Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.
Stat Methods Med Res. 2021 May;30(5):1306-1319. doi: 10.1177/0962280221995972. Epub 2021 Apr 7.
Considerations regarding clinical effectiveness and cost are essential in comparing the overall value of two treatments. There has been growing interest in methodology to integrate cost and effectiveness measures in order to inform policy and promote adequate resource allocation. The net monetary benefit aggregates information on differences in mean cost and clinical outcomes; the cost-effectiveness acceptability curve was developed to characterize the extent to which the strength of evidence regarding net monetary benefit changes with fluctuations in the willingness-to-pay threshold. Methods to derive insights from characteristics of the cost/clinical outcomes besides mean differences remain undeveloped but may also be informative. We propose a novel probabilistic measure of cost-effectiveness based on the stochastic ordering of the individual net benefit distribution under each treatment. Our approach is able to accommodate features frequently encountered in observational data including confounding and censoring, and complements the net monetary benefit in the insights it provides. We conduct a range of simulations to evaluate finite-sample performance and illustrate our proposed approach using simulated data based on a study of endometrial cancer patients.
在比较两种治疗方法的整体价值时,考虑临床效果和成本至关重要。人们越来越关注将成本和效果措施相结合的方法,以便为政策提供信息并促进资源的合理分配。净货币效益综合了平均成本和临床结果差异的信息;成本效益可接受性曲线的开发是为了描述在支付意愿阈值波动时,关于净货币效益的证据强度变化的程度。除了均值差异之外,从成本/临床结果的特征中得出见解的方法仍有待发展,但也可能具有信息性。我们提出了一种基于个体净效益分布在每种治疗下的随机排序的新的成本效益概率度量方法。我们的方法能够适应观察性数据中经常遇到的特征,包括混杂和删失,并在提供的见解中补充净货币效益。我们进行了一系列模拟来评估有限样本的性能,并使用基于子宫内膜癌患者研究的模拟数据来说明我们提出的方法。